^(125)I-HPNS-TOC的制备及其结合特性分析  

Synthesis of ^(125)I-HPNS-TOC and Analyses on Its Binding Characteristic

作　　者：孙俊杰[1] 程光亮[1] 潘林宏[1] 

机构地区：[1]安徽省蚌埠医学院核医学教研室,233030

出　　处：《实用全科医学》2006年第4期377-378,共2页Applied Journal Of General Practice

基　　金：安徽省教育厅2006年度自然科学基金项目(2006kj123c);安徽省蚌埠医学院科研基金项目(BY0409)

摘　　要：目的研究联接标记法制备碘[Tyr3]-octreotide(TOC),以及125I-HPNS-TOC与小细胞肺癌株NCI-H446的受体结合特性。方法以Bolton-Hunter试剂为联接剂,制备125I-HPNS-TOC,并以其为放射性配基,与生长抑素受体(somatostatinreceptor,SSTR)阳性细胞NCI-H446进行受体分析。结果联接标记法制备的125I-HPNS-TOC保持原有的生物活性,与SSTR结合具有高亲和力。结论用Bolton-Hunter试剂可成功制备125I-HPNS-TOC,与SSTR结合力高。本实验为125I-HPNS-TOC在受体介导的肿瘤放射性核素治疗提供了前期研究。Objective To preparing iodine labeled [Tyr3] -octrcotide （TOC） with conjugation labeling, and assessing the characteristic of 125^Ⅰ - HPNS- TOC binding to the receptors within NCI - H446 cell lines. Methods 125^Ⅰ- HPNS TOC, labeled with Bolton - Hunter reagent, were used as a radioligand to analyze the binding characteristic to somatostatin receptors （SSTR） on positive NCI H446 cell lines. Results 125^Ⅰ - HPNS- TOC, labeled with conjugation labeling, keeps its own characteristic, and has high affinity bound to SSTR. Conclusions 125^Ⅰ - HPNS - TOC can be succeed preparing with Bolton - Hunter reagents, and has high affinity to SSTR Our experiment provides an initial evidence for the using of 125^Ⅰ - HPNS- TOC in the radionuclide therapy of SSTR positive tumors mediated by receptor.

关 键 词：联接标记 125^Ⅰ-HPNS-TOC 生长抑素受体 放射性核素治疗 

分 类 号：R811[医药卫生—放射医学]